EN | TR
E-ISSN: 2146-3077
Investigation of <i>in vitro</i> Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis
PDF
Cite
Share
Request
Original Investigation
VOLUME: 46 ISSUE: 2
P: 97-101
June 2022

Investigation of in vitro Efficacy of Miltefosine on Chronic Cutaneous Leishmaniasis

Turkiye Parazitol Derg 2022;46(2):97-101
DOI: 10.4274/tpd.galenos.2022.85856
Varol Tunalı 1,2
Mehmet Harman 3
İbrahim Çavuş 4
Orçun Zorbozan 2
Ahmet Özbilgin 4
Nevin Turgay 2
1. Muğla Üniversitesi Tıp Fakültesi, Acil Tıp Anabilim Dalı, Muğla, Türkiye
2. Ege Üniversitesi Tıp Fakültesi, Parazitoloji Anabilim Dalı, İzmir, Türkiye
3. Dicle Üniversitesi Tıp Fakültesi, Dermatoloji Anabilim Dalı, Diyarbakır, Türkiye
4. Celal Bayar Üniversitesi Tıp Fakültesi, Parazitoloji Anabilim Dalı, Manisa, Türkiye
No information available.
No information available
Received Date: 04.08.2021
Accepted Date: 21.01.2022
Publish Date: 23.05.2022
PDF
Cite
Share
Request

ABSTRACT

Objective:

Leishmaniasis is the second deadliest parasitic disease in the World Health Organisation’s list of neglected diseases, following malaria. Cutaneous leishmaniasis (CL) is the most common form of the disease and it is one of the few communicable diseases with increasing incidence rates owing to factors like armed conflicts and climate change. CL can be divided into two major groups: Acute CL (ACL) and chronic CL (CCL). The aim of this study was to compare the in vitro efficacy of miltefosine and pentavalent antimony compounds in the CCL patient samples.

Methods:

Five isolates previously isolated from 5 CCL patients were included in this study. Genotyping is performed using internal transcribed spacer 1 (ITS 1) gene region real-time PCR. In vitro drug efficacy tests were applied to determine their activity against meglumine antimoniate (MA) and miltefosine. Serial dilutions (512, 256, 128, 64, 32, 16, 8 and 4 µg/mL) prepared from MA and miltefosine were prepared in 96-well flat-bottom cell culture plates and incubated at 24 °C for 48 hours. The efficacy of the drug on Leishmania spp. promastigotes after 24 and 48 hours was evaluated by hemocytometer slide and XTT cell viability test.

Results:

All of the samples were genotyped as L. tropica. Evaluation of 24 and 48 hours showed, 128 µg/mL and 256 µg/mL and 32 µg/mL and 64 µg/mL concentrations of miltefosine and MA were enough to kill all the promastigotes respectively. The results of the hemocytometer slide and XTT were consistent.

Conclusion:

There are no studies investigating the in vitro efficacy of miltefosine with the CCL patient group. To overcome the treatment challenges experienced in this special patient group, more studies are needed. According to our results, it is concluded that miltefosine is efficient for the treatment of CCL and further clinical studies with miltefosine will reveal valuable data.

Keywords: Cutaneous leishmaniasis, drug resistance, miltefosine, Turkey

References

1
Gürel MS, Yeşilova Y, Olgen MK, Ozbel Y. [Cutaneous leishmaniasis in Turkey]. Turkiye Parazitol Derg 2012; 36: 121-9.
2
Douba MD, Abbas O, Wali A, Nassany J, Aouf A, Tibbi MS, et al. Chronic cutaneous leishmaniasis, a great mimicker with various clinical presentations: 12 years experience from Aleppo. J Eur Acad Dermatol Venereol 2012; 26: 1224-9.
3
Brito NC, Rabello A, Cota GF. Efficacy of pentavalent antimoniate intralesional infiltration therapy for cutaneous leishmaniasis: A systematic review. PLoS ONE 2017; 12: e0184777.
4
Vanaerschot M, Dumetz F, Roy S, Ponte-Sucre A, Arevalo J, Dujardin JC. Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype? Expert Rev Anti Infect Ther 2014; 12: 937-46.
5
Sundar S, Olliaro PL. Miltefosine in the treatment of leishmaniasis: Clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733-40.
6
Özbilgin A, Çulha G, Uzun S, Harman M, Topal SG, Okudan F, et al. Leishmaniasis in Turkey: first clinical isolation of Leishmania major from 18 autochthonous cases of cutaneous leishmaniasis in four geographical regions. Trop Med Int Heal 2016; 21: 783-91.
7
Toz SO, Culha G, Zeyrek FY, Ertabaklar H, Alkan MZ, Vardarlı AT, et al. A real-time ITS1-PCR based method in the diagnosis and species ıdentification of Leishmania parasite from human and dog clinical samples in Turkey. PLoS Negl Trop Dis 2013; 7: e2205.
8
Tokur O, Aksoy A. In Vitro Sitotoksisite Testleri. Harran Üniv Vet Fak Derg 2017; 6: 112-8.
9
Williams C, Espinosa OA, Montenegro H, Cubilla L, Capson TL, Ortega-Barría E, et al. Hydrosoluble formazan XTT: its application to natural products drug discovery for Leishmania. J Microbiol Methods 2003; 55: 813-6.
10
Motulsky HJ. No Title [Internet]. GraphPad Statistics Guide. [cited 2020 Apr 29]. Available from: http://www.graphpad.com/guides/prism/7/statistics/index.htm
11
Ponte-Sucre A, Gamarro F, Dujardin JC, Barrett MP, López-Vélez R, García-Hernández R, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge PLoS Negl Trop Dis 2017; 11: e0006052.
12
Loiseau P, Bories C. Mechanisms of drug action and drug resistance in Leishmania as basis for therapeutic target ıdentification and design of antileishmanial modulators. Curr Top Med Chem 2006; 6: 539-50.
13
Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-26.
14
Singh OP, Singh B, Chakravarty J, Sundar S. Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective. Infect Dis Poverty 2016; 5: 19.
15
Uliana SRB, Trinconi CT, Coelho AC. Chemotherapy of leishmaniasis: present challenges. Parasitology 2018; 145: 464-80.
16
Rahman R, Goyal V, Haque R, Jamil K, Faiz A, Samad R, et al. Safety and efficacy of short course combination regimens with AmBisome, miltefosine and paromomycin for the treatment of visceral leishmaniasis (VL) in Bangladesh. PLoS Negl Trop Dis 2017; 11: e0005635.
17
Aronson N, Herwaldt BL, Libman M, Pearson R, Lopez-Velez R, Weina P, et al. Diagnosis and Treatment of Leishmaniasis: Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis 2016; 63: e202-64.
18
Escobar P, Yardley V, Croft SL. Activities of hexadecylphosphocholine (miltefosine), AmBisome, and sodium stibogluconate (Pentostam) against Leishmania donovani in immunodeficient scid mice. Antimicrob Agents Chemother 2001; 45: 1872-5.
19
Sindermann H, Engel KR, Fischer C, Bommer W. Oral miltefosine for Leishmaniasis in immunocompromised patients: compassionate use in 39 patients with HIV infection. Clin Infect Dis 2004; 39: 1520-3.
20
Dorlo TPC, van Thiel PPAM, Schoone GJ, Stienstra Y, van Vugt M, Beijnen JH, et al. Dynamics of parasite clearance in cutaneous leishmaniasis patients treated with miltefosine. PLoS Negl Trop Dis 2011; 5: e1436.
21
Soto J, Arana BA, Tolado J, Rizzo N, Vega JC, Diaz A, et al. Miltefosine for new world cutaneous leishmaniasis. Clin Infect Dis 2004; 38: 1266-72.
22
Keynan Y, Larios OE, Wiseman MC, Plourde M, Ouellette M, Rubinstein E. Use of oral miltefosine for cutaneous leishmaniasis in Canadian soldiers returning from Afghanistan. Can J Infect Dis Med 2008; 19: 394-6.
23
Killingley B, Lamb LEM, Davidson RN. Miltefosine to treat cutaneous leishmaniasis caused by Leishmania tropica. Ann Trop Med Parasitol 2009; 103: 171-5.
2024 ©️ Galenos Publishing House